STOCK TITAN

Nurix Therapeutics (NRIX) 10-K Filings

NRIX NASDAQ

Here are the 10-K annual reports from Nurix Therapeutics, Inc. (NRIX) in our archive since June 2025, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.

A 10-K covers the audited annual report, with the full financial statements, so if you follow NRIX and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full NRIX filings page.

Rhea-AI Summary

Nurix Therapeutics details in its annual report a broad clinical and partnering strategy built around targeted protein degradation for cancer and inflammatory diseases. The company’s wholly owned pipeline includes three clinical candidates: BTK degraders bexobrutideg (NX‑5948) and zelebrudomide (NX‑2127), and CBL‑B inhibitor NX‑1607.

Bexobrutideg is in a potentially pivotal Phase 2 study for heavily pretreated CLL/SLL and has U.S. Fast Track and EU PRIME designations, with additional data in Waldenström macroglobulinemia. NX‑1607 shows early immune‑oncology activity across solid tumors. Nurix also highlights its DEL‑AI discovery platform, DAC technology and collaborations with Gilead, Sanofi and Pfizer, which have provided $482 million in non‑dilutive funding and could yield up to $6.1 billion in future milestones.